COLUMBUS, Ohio, April 17 /PRNewswire-FirstCall/ -- Stonefly Communications Group, an inVentiv Health company featuring a unique Client Advisor model for healthcare advertising, has been named agency of record for Reliant Pharmaceuticals' Rythmol(R) SR (propafenone HCL) extended release capsules. The assignment will include the development of strategic and creative marketing communications for the product.
"Reliant is a pioneering pharmaceutical company that focuses on marketing innovative cardiovascular products. We couldn't be happier to be partnering with them on the marketing for Rythmol SR," said John Racik, CEO of Stonefly Communications Group.
"We are excited to work with Stonefly. Their unique marketing experience is a great complement to our team's capabilities," said Paul Huff, vice president of marketing at Reliant. "As the fastest growing branded antiarrhythmic product in the US market, Rythmol SR has already achieved great success. We look forward to partnering with Stonefly to drive product growth even further."
Reliant is a pharmaceutical company with integrated sales, marketing and development expertise that markets a portfolio of branded cardiovascular pharmaceutical products. Headquartered in New Jersey, the company focuses on marketing promotionally sensitive pharmaceutical products to the high prescribing primary care, cardiovascular and specialist physician markets in the United States. The company further enhances the value of its product portfolio by implementing strategies to extend the life cycle of the products that it markets.
Based in Columbus, Ohio, Stonefly Communications Group is a unique customer-centric healthcare advertising agency with access to a global network of communications companies in 11 countries. For more information on Stonefly Communications Group, visit http://www.stoneflygroup.com, or call 1-87-STONEFLY.
About inVentiv Health
inVentiv Health is the leading provider of commercialization and complementary services to the global pharmaceutical, life sciences and biotechnology industries. inVentiv delivers its customized clinical, sales, marketing and communications solutions through its three core business segments: inVentiv Clinical, inVentiv Communications and inVentiv Commercial. inVentiv Health currently works with over 175 unique pharmaceutical, biotech and life sciences clients, including all top 20 global pharmaceutical companies. For more information, visit http://www.inventivhealth.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause Ventiv Health's performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; uncertainties related to future incentive payments; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by Ventiv Health Inc. with the Securities and Exchange Commission for further discussion of these and other factors.
inVentiv HealthCONTACT: Media: Marcia Frederick, inVentiv Communications (inChord),+1-614-543-6281, mfrederick@inventivhealth.com; or Investors: FeliciaVonella of inVentiv Health, +1-212-308-7155, fvonella@inventivhealth.com
